Reviewed by Michael Gill, B. Sc.
25 Exparel Clinical Trials Near Me
Top Cities for Exparel Clinical Trials
Exparel Clinical Trials by Phase of Trial
Phase < 1 Exparel Clinical Trials
11Active Exparel Clinical Trials
11Number of Unique Treatments
8Number of Active Locations
Local multimodal analgesia groupTriamcinoloneAdductor Canal BlockLidocaine with BupivacainePain CatastrophizingBrain imagingESP blockLidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine
Most Recent Exparel Clinical Trials

What Are Exparel Clinical Trials?

Exparel is the brand name for the medication called Bupivacaine. It is a local anaesthetic used as an analgesic for severe pain such as dental pain or post-surgical pain. The medication is used as a nerve block for pain relief either in conjunction with opioid medications or in lieu of them, in order to help to decrease the number of prescriptions or medications on order that are contributing to the opioid crisis.

The medication is also a fast acting medication, often working as quickly as within 15 minutes of administration. Exparel clinical trials consistently work to determine what combination of medications Exparel works best with, in order to determine how to administer Exparel to produce the fastest and most effective, and long-lasting pain relief.

Why Is Exparel Being Studied In Clinical Trials?

Bupivacaine was discovered in 1957 and there is no dispute as to its effectiveness as a local anaesthetic or analgesic for pain relief. Today it is branded as Exparel. The most commonly used formulation of bupivacaine or Exparel did not receive approval by the Federal Drug Administration (FDA) until 2011.

Because there are so many modes of treatment for pain relief, Exparel is often used in conjunction with many other medications or treatments. Additionally, there are many different modes of administration with Exparel. As such, Exparel clinical trials help scientists and doctors reach those answers so that they can find the best pain relief for their patients suffering from moderate to severe pain.

How Does Exparel Treatment Work?

Exparel is a local anaesthesia and analgesic for pain relief, and it functions as a nerve blocking agent. It is often formulated with the chemical known as epinephrine, a chemical in the brain that helps us to feel stimulated with feelings of happiness or relaxation. The medication is given by injection, and its mechanisms function three phrases once inside the human system.

Once injected, the medicine undergoes three phases that includes an initial burst phase, a lag phase, and a phase of secondary release. This is how the medication can begin to act quickly, and provide pain relief that lasts a long time.

What Are Some of the Breakthrough Clinical Trials Involving Exparel?

Pain medication is an area of medicine that is complex but comprehensive. There are thousands of medications that can treat pain that are not opioids, and Exparel is one of them. The medication known as Exparel is a local analgesic for pain relief that has been used for many years. There have been some fascinating Exparel clinical trials that indicate it can be a very effective medication.

2015: A blind study on extended release Exparel was conducted in order to determine if it would be effective on patients just out of knee surgery. This study found that when Exparel was used, less pain was reported, but more pain relief was found in the control group with opioid medication, leading researchers to determine that routine use of Exparel was not recommended after knee surgery, despite its effectiveness in other areas. It is a critical piece of research because it notes the limitations of Exparel, something important in the field of pain management. This study will prevent the use of Exparel in medical environments where a better treatment method may be available.

Who Are The Key Opinion Leaders On Exparel Clinical Trial Research?

Aaron Skolnik, M.D.

Dr. Aaron Skolnik is a renowned surgeon with the Mayo Clinic who has studied and researched post-operative surgical pain, and the local anaesthetic known as Exparel, considerably. His operative work includes kidney injury and heart failure, and he is a specialist in the areas of other major organ issues include liver and lung failure. He has published a wide body of research on Exparel and other forms of pain management suitable for a post-surgical setting.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 24th, 2021

Last Reviewed: November 22nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. https://pubmed.ncbi.nlm.nih.gov/27487712 Forero M, Adhikary SD, Lopez H, Tsui C, Chin KJ. The Erector Spinae Plane Block: A Novel Analgesic Technique in Thoracic Neuropathic Pain. Reg Anesth Pain Med. 2016 Sep-Oct;41(5):621-7. doi: 10.1097/AAP.0000000000000451. https://pubmed.ncbi.nlm.nih.gov/275010163 Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006 May 13;367(9522):1618-25. Review. https://pubmed.ncbi.nlm.nih.gov/166984164 Merkel SI, Voepel-Lewis T, Shayevitz JR, Malviya S. The FLACC: a behavioral scale for scoring postoperative pain in young children. Pediatr Nurs. 1997 May-Jun;23(3):293-7. https://pubmed.ncbi.nlm.nih.gov/92208065 Guay J, Kopp S. Peripheral nerve blocks for hip fractures in adults. Cochrane Database Syst Rev. 2020 Nov 25;11:CD001159. doi: 10.1002/14651858.CD001159.pub3. https://pubmed.ncbi.nlm.nih.gov/332380436 Ely EW, Gautam S, Margolin R, Francis J, May L, Speroff T, Truman B, Dittus R, Bernard R, Inouye SK. The impact of delirium in the intensive care unit on hospital length of stay. Intensive Care Med. 2001 Dec;27(12):1892-900. Epub 2001 Nov 8. https://pubmed.ncbi.nlm.nih.gov/117970257 Myles PS, Weitkamp B, Jones K, Melick J, Hensen S. Validity and reliability of a postoperative quality of recovery score: the QoR-40. Br J Anaesth. 2000 Jan;84(1):11-5. https://pubmed.ncbi.nlm.nih.gov/107405408 Ely EW, Inouye SK, Bernard GR, Gordon S, Francis J, May L, Truman B, Speroff T, Gautam S, Margolin R, Hart RP, Dittus R. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA. 2001 Dec 5;286(21):2703-10. https://pubmed.ncbi.nlm.nih.gov/117304469 Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg. 2003 Aug;97(2):534-540. doi: 10.1213/01.ANE.0000068822.10113.9E. https://pubmed.ncbi.nlm.nih.gov/1287394910 Gerbershagen HJ, Aduckathil S, van Wijck AJ, Peelen LM, Kalkman CJ, Meissner W. Pain intensity on the first day after surgery: a prospective cohort study comparing 179 surgical procedures. Anesthesiology. 2013 Apr;118(4):934-44. doi: 10.1097/ALN.0b013e31828866b3. https://pubmed.ncbi.nlm.nih.gov/23392233